Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation

Sallah, Sabah; Husain, Aisha; Nguyen, Nam P.

doi:10.1097/00001721-200409000-00008

Cited by 7 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[8] showed that rFVIIa was able to normalize the fibrin structure in plasma containing a low level of platelets and in plasma from a patient with Glanzmanns thrombasthenia. The ability of rFVIIa to induce hemostasis under thrombocytopenic conditions has also been reported clinically [9–13] as well as in a few animal studies [14,15]. However, apart from Glanzmanns thrombasthenia, where rFVIIa is known to have a clinical effect [16,17], only few data exist on the effect of rFVIIa in situations of platelet defects.…”

Section: Introductionmentioning

confidence: 99%

rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats

Lauritzen¹,

Tranholm²,

Ezban

2009

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

To cite this article: Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogreltreated and in thrombocytopenic rats. J Thromb Haemost 2009; 7: 651-7.Summary. Background: The pharmacological effect of rFVIIa occurs at the surface of activated platelets by enhancing thrombin generation at the site of vascular damage. It is therefore important to study the effects of rFVIIa in plateletrelated bleeding situations. We examined the effect of rFVIIa and an rFVIIa-analogue, NN1731, on clopidogrel-induced and thrombocytopenic bleeding in rats. Methods and results: Clopidogrel [10 mg kg )1

show abstract

Section: Introductionmentioning

confidence: 99%

rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats

Lauritzen¹,

Tranholm²,

Ezban

2009

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…But no controlled trials exist to confirm this hypothesis. Case reports and case series show successful use of rFVIIa in DIC [16-18]. Noteworthy is that no thromboembolic complications occurred in those cases.…”

Section: Discussionmentioning

confidence: 99%

Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In this setting it was found to be effective in normalizing PT and activated partial thromboplastin time, and in controlling bleeding, without causing thromboemolic complications [52]. In a study of 18 patients with malignancy and bleeding secondary to DIC, administration of 3–10 doses of rFVIIa 90 μg/kg was effective hemostatic treatment, which the authors suggest are encouraging results, supporting the cautious use of rFVIIa in hemorrhagic DIC patients who fail to respond to conventional therapy.…”

Section: Safety Profilementioning

confidence: 98%

Untitled

Grounds

Bolan

2005

Crit Care

View full text Add to dashboard Cite

The hemostatic properties of recombinant activated factor VII (rFVIIa) are established in patients with inherited or acquired hemophilia with inhibitors and in patients with congenital factor VII deficiencies. Emerging clinical evidence suggests that there may be a wider role for rFVIIa in the management of hemorrhage associated with traumatic injury/accident and severe bleeding associated with critical surgery. This article considers recent data from studies in which rFVIIa was used in an attempt to control bleeding in clinical situations as diverse as coagulopathy associated with chronic liver disease, massive perioperative bleeding and bleeding during prostatectomy, organ transplantation and orthopedic surgery, uncontrollable obstetric hemorrhage, and intracerebral hemorrhage. In nontrauma settings involving acute and potentially life threatening bleeding, there may be a place for rFVIIa as adjunctive therapy in the control of hemostasis.

show abstract

Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation

Cited by 7 publications

References 16 publications

rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats

rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats

Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding

Untitled

Contact Info

Product

Resources

About